Opioid Enforcement The discussion started with highlights from the $2 billion Indivior settlement, which resolved criminal and civil allegations against the company, its former parent company, Reckitt Benckiser Group, and its former CEO arising from Indivior's marketing of its opioid addiction treatment drug, Suboxone. Mr. Crooke commented on this settlement, noting that it was a good example of a few areas that are continuing priorities for DOJ: opioid enforcement and individual liability. Mintz predicted in our annual health care enforcement report published earlier this year that DOJ would continue to focus on opioid-related enforcement and to use the responsible corporate officer doctrine to hold individual executives accountable. Mr.